14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PLSE vs EKSO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Ekso Bionics Holdings, Inc. (EKSO) on higher Unified Composite conviction (64.2/100 BUY vs. 58.1/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Options & Positioning), while EKSO wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $45.55 (N/M Forward P/E, -5861.2% operating margin) versus EKSO at $11.80 (N/M Forward P/E, -119.7% operating margin).
Growth vs. Quality Trade-Off: PLSE earns the overall head-to-head edge with a stronger Unified Composite Score (64.2/100 BUY vs. EKSO 58.1/100 HOLD) and 1.71β · 76% Vol risk profile, whereas EKSO leads top-line expansion (-38.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLSE vs EKSO. Trailing 12-month operating profitability (PLSE -5861.2% vs EKSO -119.7%) and valuation multiples (PLSE N/M vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PLSE vs EKSO Key Questions & Quantitative Answers
As of Nov 20, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Ekso Bionics Holdings, Inc. (EKSO) on higher Unified Composite conviction (64.2/100 BUY vs. 58.1/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Options & Positioning), while EKSO wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $45.55 (N/M Forward P/E, -5861.2% operating margin) versus EKSO at $11.80 (N/M Forward P/E, -119.7% operating margin). Growth vs. Quality Trade-Off: PLSE earns the overall head-to-head edge with a stronger Unified Composite Score (64.2/100 BUY vs. EKSO 58.1/100 HOLD) and 1.71β · 76% Vol risk profile, whereas EKSO leads top-line expansion (-38.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
PLSE leads the Growth & Scale pillar: PLSE posts +359.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (26.8% gross margin, -5861.2% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, PLSE generates $1.5M in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, PLSE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.
EKSO screens cheaper on headline valuation multiples. PLSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLSE (-60.6% ROE) versus EKSO (-107.6% ROE) capital efficiency.
In options market volatility and institutional positioning, PLSE carries 77.6% implied volatility (10th %ile, Compressed (<25th %ile)), a 43.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 76% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.